Image de couverture de livre

Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ghader Mohammadnezhad, Farhad Assarzadegan, Mohsen Koosha, Hadi Esmaily
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Headache: The Journal of Head and Face Pain
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
par: Nathaniel M. Schuster, et autres
Publié: (2025)

A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study
par: Jeffrey D. Sharon, et autres
Publié: (2024)

Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
par: Emmanuelle A. D. Schindler, et autres
Publié: (2025)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
par: Muneto Tatsumoto, et autres
Publié: (2024)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
par: Larry Charleston, et autres
Publié: (2026)

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
par: Stephen D. Silberstein, et autres
Publié: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
par: Jennifer Robblee, et autres
Publié: (2024)

Correction to “Smartphone‐delivered progressive muscle relaxation for the treatment of migraine in primary care: A randomized controlled trial”
Publié: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
par: Koichi Ikeda, et autres
Publié: (2025)

Remote electrical neuromodulation for reducing procedural pain in patients with chronic migraine receiving onabotulinumtoxinA injections: A randomized sham‐controlled study
par: Nan Cheng, et autres
Publié: (2025)

Partial rebreathing is not effective for early treatment of migraine with aura attacks: Results of a double‐blind, randomized, controlled trial ( PAREMA1 )
par: Charly Gaul, et autres
Publié: (2025)

Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy ( MOTS ) trial
par: Samantha C. Shao, et autres
Publié: (2024)

Changes in brainstem habituation during onabotulinumtoxinA treatment in chronic migraine: A prospective case–control study
par: Gerlinde Freimark, et autres
Publié: (2025)

The role of stress in the comorbidity of migraine and other chronic primary pain
par: Shi‐Jie Zhao, et autres
Publié: (2025)

Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial
par: Serena Laura Orr, et autres
Publié: (2024)

IV dexamethasone as adjuvant therapy to metoclopramide for acute posttraumatic headache in the ED : A randomized controlled trial
par: Kareem Joudi, et autres
Publié: (2026)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
par: Shuu‐Jiun Wang, et autres
Publié: (2024)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
par: Geneviève Tourigny‐Ruel, et autres
Publié: (2026)

Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trials
par: Richard Bertz, et autres
Publié: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
par: Kara S. Graves, et autres
Publié: (2026)

Glial activation in pain and emotional processing regions in the nitroglycerin mouse model of chronic migraine
par: Haley C. Cropper, et autres
Publié: (2024)

Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache
par: Andrew Blumenfeld, et autres
Publié: (2024)

Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo‐controlled study in healthy adults
par: Rajinder Bhardwaj, et autres
Publié: (2024)

Sex influences the progression of cephalic mechanical and light hypersensitivities in a mouse model of chronic migraine
par: Marie Raquin, et autres
Publié: (2025)

Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
par: Alex Jaimes, et autres
Publié: (2024)

Early effect of onabotulinumtoxinA on EEG ‐based functional connectivity in patients with chronic migraine: A pilot study
par: Matteo Conti, et autres
Publié: (2024)

The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta‐analysis
par: Rebecca Lindsay, et autres
Publié: (2024)

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
par: Anna de Dios, et autres
Publié: (2024)

Engagement and predictors of use of a smartphone app for migraine self‐management: A secondary analysis of the EMMA trial
par: Stefanie Lysk, et autres
Publié: (2025)

Efficacy of an educational website on headaches in schoolchildren: A cluster‐randomized controlled trial
par: Henrike Goldstein, et autres
Publié: (2025)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
par: Yunus Emre Meydanal, et autres
Publié: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
par: Graham A. McLeod, et autres
Publié: (2025)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
par: Anna Gryglas‐Dworak, et autres
Publié: (2024)

The safety and feasibility of transcranial direct current stimulation and exercise therapy for the treatment of cervicogenic headaches: A randomized pilot trial
par: Kaiden Jobin, et autres
Publié: (2025)

Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study
par: Christopher C. Anderson, et autres
Publié: (2024)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
par: Rikki Mangrum, et autres
Publié: (2024)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
par: Joaquín Borrás‐Blasco, et autres
Publié: (2025)

Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study
par: Devin Teichrow, et autres
Publié: (2026)

Reliability, validity, and responsiveness of the Arabic version of HIT ‐6 questionnaire in patients with migraine indicated for preventive therapy: A multi‐center study
par: Mona Hussein, et autres
Publié: (2024)

Clinical factors associated with day‐to‐day peak pain severity in individuals with chronic migraine: A cohort study using daily prospective diary data
par: Marina Vives‐Mestres, et autres
Publié: (2024)